AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12147008 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning and cueing approach
Number of subjects: 7
Study 12147008 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralesional limb activation approach
Number of subjects: 7
Study 10411846 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting with the heparin‐coated Palmaz‐Schatz stent
Number of subjects: 410
Study 10411846 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (PTCA)
Number of subjects: 410
Study 7738626 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2 micrograms/kg/min continuous infusion over 48 hours)
Number of subjects: 42
Study 7738626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7738626 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 42
Study 1876891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (LID) 2 mg/min constant-rate infusion after a bolus of LID 100 mg (Group A)
Number of subjects: 34
Study 1876891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (LID) 2 mg/min constant-rate infusion after a bolus of LID 100 mg + Magnesium Sulfate (M) 2.5 mg/min (Group B)
Number of subjects: 34
Study 1876891 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (LID) alone (Group A)
Number of subjects: 34
Study 1876891 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (LID) + Magnesium (Group B)
Number of subjects: 34
Study 6348397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 27
Study 6348397 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 27
Study 6348397 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney Allotransplantation (KT)
Number of subjects: 27
Study 29955932 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg daily)
Number of subjects: 95
Study 29955932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 28475465 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group (6 days of food restriction)
Number of subjects: 11
Study 28475465 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained body weight)
Number of subjects: 11
Study 25307158 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 70
Study 25307158 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 70
Study 25134291 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues (subcutaneous triptorelin depot injection) before hydrothermal endometrial ablation (HTA)
Number of subjects: 30
Study 25134291 — intervention group
Group type: COMPARATOR
Intervention: Control (no presurgical treatment)
Number of subjects: 30
Study 22481014 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids 4 g/day starting 3 days before surgery until 5 days after surgery
Number of subjects: 121
Study 22481014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 22481014 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids
Number of subjects: 121
Study 19859699 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose tablets
Number of subjects: 928
Study 19859699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sorbitol) tablets
Number of subjects: 928
Study 19859699 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose tablets with other medication (NRT/bupropion)
Number of subjects: 928
Study 19859699 — intervention group
Group type: COMPARATOR
Intervention: Placebo with other medication (NRT/bupropion)
Number of subjects: 928
Study 19859699 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose tablets without other medication
Number of subjects: 928
Study 19859699 — intervention group
Group type: COMPARATOR
Intervention: Placebo without other medication
Number of subjects: 928
Study 16981901 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg once daily for 14 days)
Number of subjects: 18
Study 16981901 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (2 mg oral and 1 mg i.v., 1 day apart)
Number of subjects: 18
Study 16275518 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial velocity imaging-derived RV IVRT (IVRT')
Number of subjects: 33
Study 16275518 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate-corrected IVRT' derived from the basal RV free wall segment
Number of subjects: 33
Study 16275518 — intervention group
Group type: COMPARATOR
Intervention: Tricuspid regurgitation-derived PAP systolic
Number of subjects: 33
Study 12187217 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the sacral roots (15 Hz, 50% intensity output for 5 seconds per minute for 30 minutes)
Number of subjects: 48
Study 12187217 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation group
Number of subjects: 48
Study 12187217 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation group
Number of subjects: 48
Study 9925698 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 95)
Number of subjects: 183
Study 9925698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer at the distal bile duct group (n = 9)
Number of subjects: 183
Study 9925698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile duct stone group (n = 56)
Number of subjects: 183
Study 9925698 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive jaundice group (n = 17)
Number of subjects: 183
Study 9925698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer extension to the common hepatic duct group (n = 4)
Number of subjects: 183
Study 9925698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosing cholangitis group (n = 2)
Number of subjects: 183
Study 7485932 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 811
Study 7485932 — intervention group
Group type: COMPARATOR
Intervention: Parenteral morphine
Number of subjects: 811
Study 7485932 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous oral herpes
Number of subjects: 811
Study 7485932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pruritus
Number of subjects: 811
Study 2372330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory acoustic stimulation
Number of subjects: 0
Study 2372330 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibratory acoustic stimulation)
Number of subjects: 0
Study 369868 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1.0 g x 4 for 2 days, then 0.5 g x 4 for the next 2 days)
Number of subjects: 24
Study 369868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 369868 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 24
Study 31118315 — intervention group
Group type: EXPERIMENTAL
Intervention: Data elements for electronic medical records (EMRs) for mental disorders
Number of subjects: 50
Study 28148492 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-1 (1 min rest between sprints)
Number of subjects: 14
Study 28148492 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-5 (5 min rest between sprints)
Number of subjects: 14
Study 28148492 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Rest-1 and Rest-5)
Number of subjects: 14
Study 25975702 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental training program
Number of subjects: 40
Study 25975702 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 24051231 — intervention group
Group type: EXPERIMENTAL
Intervention: Theanine (200 mg, twice a day, after breakfast and lunch)
Number of subjects: 20
Study 24051231 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 20
Study 24051231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 22151785 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (1200 μg allicin, three times daily)
Number of subjects: 117
Study 22151785 — intervention group
Group type: COMPARATOR
Intervention: d‐penicillamine (250 mg, three times daily)
Number of subjects: 117
Study 19689918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 292
Study 19689918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 17482846 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced anticoagulation (INR target 1.8)
Number of subjects: 131
Study 17482846 — intervention group
Group type: COMPARATOR
Intervention: Full anticoagulation (INR target 2.5 or more)
Number of subjects: 131
Study 17482846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 131
Study 15063053 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural coordination during reading task on various surfaces
Number of subjects: 31
Study 15063053 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural sway (head motion)
Number of subjects: 31
Study 11593322 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly CMV antigenemia testing with ganciclovir administration for a positive result
Number of subjects: 118
Study 11593322 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy for CMV on day 35 post BMT
Number of subjects: 118
Study 11593322 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy arm
Number of subjects: 118
Study 11593322 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigenemia arm
Number of subjects: 118
Study 10186958 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute treatment of concentrated (5 mg/mL) albuterol in the Circulaire nebulizer
Number of subjects: 0
Study 10186958 — intervention group
Group type: COMPARATOR
Intervention: Conventional unit dose treatment
Number of subjects: 0
Study 8115670 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (10, 20 or 30 mg/day for three weeks)
Number of subjects: 20
Study 3398512 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at a pace that elicited 60% of V̇O2max, for 30 minutes, three times weekly for twelve weeks.
Number of subjects: 26
Study 3398512 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 26
Study 29411268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with orange juice
Number of subjects: 32
Study 29411268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with water
Number of subjects: 32
Study 29411268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with omeprazole 20 mg and water
Number of subjects: 32
Study 29411268 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole co-administration
Number of subjects: 32
Study 29411268 — intervention group
Group type: COMPARATOR
Intervention: All treatments (orange juice, water, omeprazole)
Number of subjects: 32
Study 27029778 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC-TDF
Number of subjects: 1549
Study 27029778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1549
Study 24738463 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of urethral catheter (1-2 days)
Number of subjects: 128
Study 24738463 — intervention group
Group type: COMPARATOR
Intervention: Control group (catheter removal at 5-7 days)
Number of subjects: 128
Study 23431246 — intervention group
Group type: EXPERIMENTAL
Intervention: HE3286
Number of subjects: 0
Study 23431246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20735398 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)
Number of subjects: 267
Study 20735398 — intervention group
Group type: EXPERIMENTAL
Intervention: E-IPI
Number of subjects: 267
Study 20735398 — intervention group
Group type: EXPERIMENTAL
Intervention: R-IPI
Number of subjects: 267
Study 19244630 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 5 mg IM
Number of subjects: 87
Study 19244630 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg IM
Number of subjects: 87
Study 16318615 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 70
Study 16318615 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 70
Study 16318615 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 70
Study 12622339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of 0.65 g/kg alcohol and 4 mg/kg caffeine
Number of subjects: 21
Study 12622339 — intervention group
Group type: COMPARATOR
Intervention: 0.65 g/kg alcohol alone
Number of subjects: 21
Study 12622339 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/kg caffeine alone
Number of subjects: 21
Study 10589107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention strategy using a geropsychiatric nurse and trained older adult volunteers
Number of subjects: 139
Study 10589107 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 139
Study 8743003 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide thrice daily
Number of subjects: 16
Study 8743003 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 16
Study 8743003 — intervention group
Group type: COMPARATOR
Intervention: 0.5% betaxolol twice daily
Number of subjects: 16
Study 1889719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg nightly (continuous dosing)
Number of subjects: 17
Study 1889719 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg nightly (intermittent dosing)
Number of subjects: 17
Study 1889719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intermittent and continuous dosing with ranitidine
Number of subjects: 17
Study 6614662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and/or oral potassium chloride supplementation during preoperative bowel preparation (60 mmol average supplementation)
Number of subjects: 53
Study 6614662 — intervention group
Group type: COMPARATOR
Intervention: No potassium chloride supplementation
Number of subjects: 53
Study 31335755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/propofol admixture (0.5 mg/kg of ketamine and propofol each)
Number of subjects: 160
Study 31335755 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.15 mg/kg)
Number of subjects: 160
Study 29519598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bony fixation with Kirschner (K-) wire
Number of subjects: 55
Study 29519598 — intervention group
Group type: COMPARATOR
Intervention: Suture fixation
Number of subjects: 55
Study 27179770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (IV and topical TXA)
Number of subjects: 84
Study 27179770 — intervention group
Group type: COMPARATOR
Intervention: IV-TXA group
Number of subjects: 84
Study 24121915 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg)
Number of subjects: 25
Study 24121915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline solution)
Number of subjects: 25
Study 22124602 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical therapy focusing on strengthening exercises of the rotator cuff and scapula stabilizers (PT-group)
Number of subjects: 36
Study 22124602 — intervention group
Group type: COMPARATOR
Intervention: Home-based movement exercises (H-group)
Number of subjects: 36
Study 20634797 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/day)
Number of subjects: 19
Study 20634797 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg/day)
Number of subjects: 19
Study 20634797 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day)
Number of subjects: 19
Study 20634797 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 19
Study 18070469 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure of atrial septal defect (ASD)
Number of subjects: 264
Study 18070469 — intervention group
Group type: COMPARATOR
Intervention: Preoperative atrial tachyarrhythmias (AT)
Number of subjects: 264
Study 18070469 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 264
Study 18070469 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of preoperative AT
Number of subjects: 264
Study 18070469 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial enlargement
Number of subjects: 264
Study 15223106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol valerate 2 mg per day plus normegestrol acetate 2.5 mg per day for 12 months
Number of subjects: 199
Study 15223106 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 microg per day) plus normegestrol acetate 2.5 mg per day for 12 months
Number of subjects: 199
Study 15223106 — intervention group
Group type: COMPARATOR
Intervention: Both groups (oral and transdermal)
Number of subjects: 199
Study 11437864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel dressing (Group B)
Number of subjects: 20
Study 11437864 — intervention group
Group type: COMPARATOR
Intervention: Saline-moistened gauze (Group A)
Number of subjects: 20
Study 9679581 — intervention group
Group type: COMPARATOR
Intervention: UFT as adjuvant chemotherapy for bladder cancer (12 patients)
Number of subjects: 22
Study 9679581 — intervention group
Group type: COMPARATOR
Intervention: UFT combined with endocrine therapy for prostate cancer (10 patients)
Number of subjects: 22
Study 7852207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquirable skill condition
Number of subjects: 76
Study 7852207 — intervention group
Group type: COMPARATOR
Intervention: Entity condition
Number of subjects: 76
Study 7852207 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 76
Study 2529028 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of HPR
Number of subjects: 14
Study 2529028 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of HPR
Number of subjects: 14
Study 2529028 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of HPR
Number of subjects: 14
Study 2529028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1100225 — intervention group
Group type: EXPERIMENTAL
Intervention: NSC-122819 (50 mg/m2/dose iv twice weekly for 4 weeks)
Number of subjects: 39
Study 1100225 — intervention group
Group type: EXPERIMENTAL
Intervention: NSC-141540 (75 mg/m2/dose iv twice weekly for 4 weeks)
Number of subjects: 39
Study 1100225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NSC-122819 and NSC-141540
Number of subjects: 39
Study 31273569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 30
Study 31273569 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 30
Study 31273569 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 30
Study 29728662 — intervention group
Group type: EXPERIMENTAL
Intervention: Central retinal arteriolar equivalents (CRAE) in men with a 20% shorter leukocyte telomere length (LTL)
Number of subjects: 168
Study 29728662 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriole-to-venule ratio (AVR) in men with a 20% shorter leukocyte telomere length (LTL)
Number of subjects: 168
Study 29728662 — intervention group
Group type: COMPARATOR
Intervention: Retinal microvascular traits in women
Number of subjects: 168
Study 27398781 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice intervention
Number of subjects: 217
Study 27398781 — intervention group
Group type: EXPERIMENTAL
Intervention: MET + CBT
Number of subjects: 217
Study 27398781 — intervention group
Group type: COMPARATOR
Intervention: Brief psychoeducation
Number of subjects: 217
Study 27398781 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 217
Study 24689339 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms feedback via personalised Facebook private messages over three sessions
Number of subjects: 95
Study 24689339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 95
Study 23598288 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline infusion
Number of subjects: 25
Study 23598288 — intervention group
Group type: COMPARATOR
Intervention: Plasmalyte infusion
Number of subjects: 25
Study 20455959 — intervention group
Group type: EXPERIMENTAL
Intervention: Live maggots applied to wound cultures
Number of subjects: 0
Study 17962237 — intervention group
Group type: EXPERIMENTAL
Intervention: CRx-102
Number of subjects: 83
Study 17962237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 15347712 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-5IA SPECT imaging of nAChRs
Number of subjects: 0
Study 11181464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg/d
Number of subjects: 732
Study 11181464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/d
Number of subjects: 732
Study 11181464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 11181464 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 732
Study 11181464 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Vitamin E
Number of subjects: 732
Study 9835978 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous injection (CA) group, n = 21
Number of subjects: 42
Study 9835978 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) group, n = 21
Number of subjects: 42
Study 8129127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillar infiltration with 0.25% bupivacaine 5 min before surgical incision (n = 12)
Number of subjects: 35
Study 8129127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillar infiltration with 0.25% bupivacaine administered after both tonsils had been surgically removed (n = 12)
Number of subjects: 35
Study 8129127 — intervention group
Group type: COMPARATOR
Intervention: Infiltration with isotonic saline 5 min before the operation (n = 11)
Number of subjects: 35
Study 8129127 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative bupivacaine group (n = 12)
Number of subjects: 35
Study 8129127 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative bupivacaine group (n = 12)
Number of subjects: 35
Study 8129127 — intervention group
Group type: COMPARATOR
Intervention: Saline group (n = 11)
Number of subjects: 35